AR057872A1 - Inhibidores de la proteina activadora de 5-lipoxigenasa (flap) - Google Patents
Inhibidores de la proteina activadora de 5-lipoxigenasa (flap)Info
- Publication number
- AR057872A1 AR057872A1 ARP060104837A ARP060104837A AR057872A1 AR 057872 A1 AR057872 A1 AR 057872A1 AR P060104837 A ARP060104837 A AR P060104837A AR P060104837 A ARP060104837 A AR P060104837A AR 057872 A1 AR057872 A1 AR 057872A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- nr9c
- alkyl
- nhc
- Prior art date
Links
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 title abstract 2
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 150000002617 leukotrienes Chemical class 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 101150036626 LSR gene Proteins 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
Abstract
Se describen en la presente compuestos y composiciones farmacéuticas que contienen tales compuestos, que modulan la actividad de la proteína activadora de la 5-lipoxigenasa (FLAP). Estos compuestos son utiles para tratar enfermedades respiratorias, cardiovasculares, y otras afecciones o enfermedades leucotrieno-dependientes o mediadas por leucotrienos. Reivindicacion 1: Un compuesto que tiene la estructura de formula (1): en la cual, Z se selecciona de [C(R1)2]m[C(R2)2]n, [C(R2)2]n[C(R1)2]mO, O[C(R1)2]m[C(R2)2]n, [C(R2)2]nO[C(R1)2]n o [C(R1)2]nO[C(R2)2]n, donde cada R1 es independientemente H, CF3, o un alquilo inferior opcionalmente sustituido y dos R1 sobre el mismo carbono pueden unirse para formar un carbonilo (=O); y cada R2 es independientemente H, OH, OMe, CF3, o un alquilo inferior opcionalmente sustituido y dos R2 sobre el mismo carbono pueden unirse para formar un carbonilo (=O); m es 0, 1 o 2; cada n es independientemente 0, 1, 2 o 3; Y es H o -(arilo sustituido o no sustituido); o -(heteroarilo sustituido o no sustituido); donde cada sustituyente en Y o Z es (LsRs)j, donde cada Ls se selecciona independientemente en un enlace, -O-, -C(=O)-, -S-, -S(=O), -S(=O)2-, -NHC(O)-, -C(O)NH-, S(=O)2NH-, -NHS(=O)2, - OC(O)NH-, -NHC(O)O-, -OC(O)O-, -NHC(O)NH-, -C(O)O-, -OC(O)-, alquilo C1-6 sustituido o no sustituido, alquenilo C2-6, fluoroalquilo -C1-6, heteroarilo sustituido o no sustituido, arilo sustituido o no sustituido, o heterociclo sustituido o no sustituido; y cada Rs se selecciona independientemente de H, halogeno, -N(R4)2, -CN, -NO2, N3, -S(=O)2NH2, alquilo inferior sustituido o no sustituido, cicloalquilo inferior sustituido o no sustituido, fluoroalquilo C1-C6, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, o heteroalquilo sustituido o no sustituido; donde j es 0, 1, 2, 3 o 4; R6 es H, L2-(alquilo sustituido o no sustituido, L2-(cicloalquilo sustituido o no sustituido), L2-(alquenilo sustituido o no sustituido, L2-(cicloalquenilo sustituido o no sustituido), L2-(heterociclo sustituido o no sustituido, L2-(heteroarilo sustituido o no sustituido), o L2-(arilo sustituido o no sustituido), donde L2 es un enlace, O, S, -S(=O), C(O), -CH(OH), - (alquilo C1-6 sustituido o no sustituido), o -(alquenilo C2-6sustituido o no sustituido); R7 es L3-X-L4-G1, donde, L3 es a alquilo sustituido o no sustituido; X es un enlace, O, -C(=O), -CR9(OR9), S, -S(=O)2, -NR9, -NR9C(O), -C(O)NR9, -NR9C(O)NR9-; L4 es un enlace, o un alquilo sustituido o no sustituido; G1 es H, tetrazolilo, NHS(=O)2R8, S(=O)2N(R9)2, -OR9, -C(=O)CF3, -C(O)NHS(=O)2R8, -S(=O)2NHC(O)R9, CN, N(R9)2, -N(R9)C(O)R9, -C(=NR10)N(R9)2, -NR9C(=NR10)N(R9)2, -NR9C(=CR10)N(R9)2, - C(O)NR9C(=NR10)N(R9)2, -C(O)NR9C(=CR10)N(R9)2, -CO2R9, -C(O)R9, -CON(R9)2, -SR8, -S(=O)R8, -S(=O)2R8, -L5-(alquilo sustituido o no sustituido), -L5-(alquenilo sustituido o no sustituido), -L5-(heteroarilo sustituido o no sustituido), o -L5-(arilo sustituido o no sustituido), donde L5 es -OC(O)O-, -NHC(O)NH-, -NHC(O)O, -O(O)CNH-, -NHC(O), -C(O)NH, -C(O)O u -OC(O); o G1 es W-G5, donde W es un arilo sustituido o no sustituido, heterociclo sustituido o no sustituido o heteroarilo sustituido o no sustituido y G5 es H, tetrazolilo, -NHS(=O)2R8, S(=O)2N(R9)2, OH, -OR8, -C(=O)CF3, -C(O)NHS(=O)2R8, -S(=O)2NHC(O)R9, CN, N(R9)2, -N(R9)C(O)R9, -C(=NR10)N(R9)2, -NR9C(=NR10)N(R9)2, -NR9C(=CR10)N(R9)2, -C(O)NR9C(=NR10)N(R9)2, -C(O)NR9C(=CR10)N(R9)2, - CO2R9, -C(O)R9, -CON(R9)2, -SR8, -S(=O)R8, o -S(=O)2R8; cada R8 se selecciona independientemente de alquilo inferior sustituido o no sustituido, cicloalquilo inferior sustituido o no sustituido, fenilo sustituido o no sustituido o bencilo sustituido o no sustituido; cada R9 se selecciona independientemente de H, alquilo inferior sustitutido o no sustituido, cicloalquilo inferior sustituido o no sustituido, fenilo sustituido o no sustituido o bencilo sustituido o no sustituido; o dos grupos R9 pueden formar juntos un anillo heterocíclico de 5, 6, 7 u 8 miembros; o R8 y R9 pueden formar juntos un anillo heterocíclico de 5, 6, 7 u 8 miembros y cada R10 se selecciona independientemente de H, -S(=O)2R8, -S(=O)2NH2 -C(O)R8, -CN, -NO2, heteroarilo o heteroalquilo; R5 es H halogeno, alquilo C1-6sustituido o no sustituido, O-alquilo C1-6sustituido o no sustituido; R11 es L7-L10-G6, donde L7 es un enlace, -C(O), -C(O)NH, -NHC(O), o (alquilo C1-6sustituido o no sustituido); L10 es un enlace, (alquilo sustituido o no sustituido), (cicloalquilo sustituido o no sustituido), (heteroarilo sustituido o no sustituido), (arilo sustituido o no sustituido), o (heterociclo sustituido o no sustituido); G6 es OR9, -C(=O)R9, -SR8, -S(=O)R8, - S(=O)2R8, N(R9)2, tetrazolilo, -NHS(=O)2R8, -S(=O)2N(R9)2, -C(O)NHS(=O)2R8, -S(=O)2NHC(O)R9, -C(=O)N(R9)2, NR9C(O)R9, C(R9)2C(=O)N(R9)2-C(=NR10)N(R9)2, -NR9C(=NR10)N(R9)2, -NR9C(=CR10)N(R9)2, -L5-(alquilo sustituido o no sustituido), -L5-(alquenilo sustituido o no sustituido), -L5-(heteroarilo sustituido o no sustituido), o -L5-(arilo sustituido o no sustituido), donde L5 es -O-, C(=O), S, S(=O), S(=O)2, -NH, -NHC(O)O, -NHC(O)NH-, -OC(O)O-, -OC(O)NH-, -NHC(O), -C(O)NH, -C(O)O u -OC(O) o G6 es W-G7, donde W es (heterociclo sustituido o no sustituido), (arilo sustituido o no sustituido) o un (heteroarilo sustituido o no sustituido) y G7 es H, halogeno, CN, NO2, N3, CF3, OCF3, C1-6 alquilo, C3-6 cicloalquilo, fluoroalquilo C1-6, tetrazolilo, NHS(=O)2R8, S(=O)2N(R9)2, OH, -OR8, -C(=O)CF3, -C(O)NHS(=O)2R8, -S(=O)2NHC(O)R9, CN, N(R9)2, -N(R9)C(O)R9, -C(=NR10)N(R9)2, -NR9C(=NR10)N(R9)2, -NR9C(=CR10)N(R9)2, -C(O)NR9C(=NR10)N(R9)2, -C(O)NR9C(=CR10)N(R9)2, -CO2R9, -C(O)R9, - CON(R9)2, -SR8, -S(=O)R8, o -S(=O)2R8, -L5-(alquilo sustituido o no sustituido), -L5-(alquenilo sustituido o no sustituido), -L5-(heteroalquilo sustituido o no sustituido), -L5-(heteroarilo sustituido o no sustituido), -L5-(heterociclo sustituido o no sustituido), o -L5-(arilo sustituido o no sustituido), donde L5 es un enlace, -O-, C(=O), S, S(=O), S(=O)2, -NH, -NHC(O)O, NHC(O)NH-, -OC(O)O-, .OC(O)NH, -C(O)NH, -C(O)O u -OC(O); con la salvedad de que R11 comprende almenos un resto aromático (no sustituido o sustituido) y al menos un resto cíclico (no sustituido o sustituido), donde el resto cíclico (no sustituido o sustituido) es un grupo heterocíclico (no sustituido o sustituido) o un grupo heteroarilo (no sustituido o sustituido) y R11 no es un grupo tienil-fenilo; R12 es H, (alquilo C1-6sustituido o no sustituido), (cicloalquilo C3-6 sustituido o no sustituido); o su metabolito activo, o solvato, o sal aceptable para uso farmacéutico, o profármaco aceptable para uso farmacéutico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73403005P | 2005-11-04 | 2005-11-04 | |
US74717406P | 2006-05-12 | 2006-05-12 | |
US82334406P | 2006-08-23 | 2006-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057872A1 true AR057872A1 (es) | 2007-12-26 |
Family
ID=37546284
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104837A AR057872A1 (es) | 2005-11-04 | 2006-11-03 | Inhibidores de la proteina activadora de 5-lipoxigenasa (flap) |
ARP060104838A AR056214A1 (es) | 2005-11-04 | 2006-11-03 | Inhibidores de la proteina que activa la 5- lipooxigenasa (flap) |
ARP060104861A AR056215A1 (es) | 2005-11-04 | 2006-11-06 | Derivados de indol como inhibidores de la proteina activadora de 5-lipoxigenasa (flap), composiciones farmaceuticas que los comprenden y su uso en el tratamiento de trastornos respiratorios e inflamatorios |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104838A AR056214A1 (es) | 2005-11-04 | 2006-11-03 | Inhibidores de la proteina que activa la 5- lipooxigenasa (flap) |
ARP060104861A AR056215A1 (es) | 2005-11-04 | 2006-11-06 | Derivados de indol como inhibidores de la proteina activadora de 5-lipoxigenasa (flap), composiciones farmaceuticas que los comprenden y su uso en el tratamiento de trastornos respiratorios e inflamatorios |
Country Status (17)
Country | Link |
---|---|
US (3) | US8841295B2 (es) |
EP (2) | EP1943266A4 (es) |
JP (2) | JP2009514959A (es) |
KR (1) | KR20080066989A (es) |
AR (3) | AR057872A1 (es) |
AU (2) | AU2006311796A1 (es) |
BR (1) | BRPI0618047A2 (es) |
CA (2) | CA2628233A1 (es) |
CR (1) | CR9949A (es) |
EA (1) | EA200801164A3 (es) |
GB (1) | GB2431927B (es) |
IL (1) | IL190872A0 (es) |
MA (1) | MA29932B1 (es) |
NO (1) | NO20081839L (es) |
SG (1) | SG165387A1 (es) |
TW (4) | TW201402562A (es) |
WO (2) | WO2007056220A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070219206A1 (en) * | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US20070225285A1 (en) * | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US20070244128A1 (en) * | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
EP2086531A4 (en) * | 2006-11-30 | 2009-09-30 | Amira Pharmaceuticals Inc | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS |
TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
BRPI0912267A2 (pt) * | 2008-05-23 | 2015-10-13 | Amira Pharmaceuticals Inc | sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável. |
US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US20120027842A1 (en) * | 2008-12-23 | 2012-02-02 | Amira Pharmaceuticals, Inc. | Topical formulations of flap inhibitors for administration to an eye |
JP2012513406A (ja) * | 2008-12-23 | 2012-06-14 | パンミラ ファーマシューティカルズ,エルエルシー. | 皮膚科学の疾病の処置のためのflap阻害剤の局所製剤 |
KR101357438B1 (ko) | 2009-04-29 | 2014-02-06 | 아마린 코포레이션 피엘씨 | Epa 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법 |
JP2013500979A (ja) * | 2009-07-31 | 2013-01-10 | パンミラ ファーマシューティカルズ,エルエルシー. | Dp2受容体アンタゴニストの皮膚用製剤 |
CN102822166A (zh) * | 2009-11-03 | 2012-12-12 | 葛兰素集团有限公司 | 制备5-脂氧合酶活化蛋白抑制剂及其中间体的方法 |
US8420655B2 (en) | 2009-12-04 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
WO2011153433A1 (en) * | 2010-06-04 | 2011-12-08 | Colin Hislop | Spla2 inhibitor conjugate compounds and methods of use |
MX2013001872A (es) | 2010-08-16 | 2013-09-02 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrieno. |
US8580829B2 (en) | 2010-08-26 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
IN2013DN02555A (es) | 2010-09-23 | 2015-08-07 | Boehringer Ingelheim Int | |
WO2012040137A1 (en) * | 2010-09-23 | 2012-03-29 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
EP2632915B1 (en) * | 2010-10-29 | 2015-08-12 | Boehringer Ingelheim International GmbH | Benzimidazole inhibitors of leukotriene production |
WO2012061169A1 (en) * | 2010-11-01 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
EP2865756A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene. |
ES2878405T3 (es) | 2014-02-04 | 2021-11-18 | Bioscience Pharma Partners Llc | Uso de inhibidores de flap para reducir la lesión mediada por neuroinflamación en el sistema nervioso central |
CN104277042A (zh) * | 2014-10-15 | 2015-01-14 | 湖南华腾制药有限公司 | 一种咪唑并吡啶衍生物的制备方法 |
HUE047445T2 (hu) * | 2015-05-04 | 2020-04-28 | Astrazeneca Ab | Pirazol-származékok, amelyek 5-lipoxigenáz aktiváló fehérje (FLAP) gátlókként használhatók |
SG11201903414SA (en) * | 2016-10-28 | 2019-05-30 | Astrazeneca Ab | Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide |
Family Cites Families (210)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2431491A1 (fr) * | 1978-07-18 | 1980-02-15 | Delalande Sa | Nouveaux derives aminoalkoxy-5 benzofurannes et indoles, leur procede de preparation et leur application en therapeutique |
DK151884C (da) | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
JPS60123485A (ja) | 1983-12-08 | 1985-07-02 | Yoshitomi Pharmaceut Ind Ltd | インド−ル−3−カルボキサミド誘導体 |
US5109009A (en) | 1985-03-08 | 1992-04-28 | Leo Pharmaceutical Products Ltd. | Quinoline and pyridine compounds and inhibition of 5-lipoxygenases therewith |
IE58870B1 (en) | 1985-03-08 | 1993-11-17 | Leo Pharm Prod Ltd | Pyridine derivatives |
DE3632411A1 (de) | 1986-09-24 | 1988-04-07 | Merck Patent Gmbh | Verfahren zur herstellung von ethanderivaten |
IL84796A (en) * | 1986-12-17 | 1992-03-29 | Merck Frosst Canada Inc | Substituted n-benzyl-indoles and pharmaceutical compositions containing them |
US5081138A (en) * | 1986-12-17 | 1992-01-14 | Merck Frosst Canada, Inc. | 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith |
US5225421A (en) | 1986-12-17 | 1993-07-06 | Merck Frosst Canada, Inc. | 3-hetero-substituted-N-benzyl-indoles and medical methods of use therefor |
MY103259A (en) * | 1987-04-15 | 1993-05-29 | Ici America Inc | Aliphatic carboxamides |
CA1337202C (en) * | 1988-04-13 | 1995-10-03 | Victor Giulio Matassa | Cyclic amides which are leukotriene antagonists |
US5232916A (en) | 1988-06-27 | 1993-08-03 | Merck Frosst Canada, Inc. | Quinoline ether alkanoic acids |
NZ234883A (en) * | 1989-08-22 | 1995-01-27 | Merck Frosst Canada Inc | Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof |
US5252585A (en) | 1992-02-03 | 1993-10-12 | Merck Frosst Canada, Inc. | Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes |
US5272145A (en) | 1989-08-22 | 1993-12-21 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
CA1337427C (en) | 1989-08-22 | 1995-10-24 | Merck Frosst Canada Incorporated | (quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
US5204344A (en) | 1989-08-22 | 1993-04-20 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
US5420289A (en) * | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
US5229516A (en) * | 1989-10-27 | 1993-07-20 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
CA2032253C (en) | 1989-12-15 | 2000-11-28 | John W. Gillard | 5-lipoxygenase activating protein |
US5093356A (en) | 1990-01-16 | 1992-03-03 | Merck Frosst Canada, Inc. | Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
US5081145A (en) | 1990-02-01 | 1992-01-14 | Merck Frosst Canada, Inc. | Indole-2-alkanoic acids compositions of and anti allergic use thereof |
US5095031A (en) | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
JPH0764841B2 (ja) | 1990-10-03 | 1995-07-12 | ファイザー製薬株式会社 | インドール誘導体およびその用途 |
US5182367A (en) | 1990-11-30 | 1993-01-26 | Merck & Co., Inc. | 5-lipoxygenase activating protein |
CA2060557C (en) * | 1991-02-05 | 2002-06-04 | Merck Frosst Canada Incorporated | (quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes |
GB9108811D0 (en) | 1991-04-24 | 1991-06-12 | Erba Carlo Spa | N-imidazolyl derivatives of substituted indole |
US5202321A (en) | 1991-06-13 | 1993-04-13 | Merck Frosst Canada, Inc. | Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis |
JPH06100551A (ja) | 1991-09-06 | 1994-04-12 | Dainippon Ink & Chem Inc | 光学活性な2,5置換テトラヒドロフラン誘導体、その製造方法、その誘導体を含む液晶組成物及び液晶表示素子 |
US5290798A (en) | 1991-09-30 | 1994-03-01 | Merck Frosst Canada, Inc. | (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
CA2079374C (en) * | 1991-09-30 | 2003-08-05 | Merck Frosst Canada Incorporated | (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5273980A (en) | 1991-09-30 | 1993-12-28 | Merck Frosst Canada Inc. | Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
US5389650A (en) * | 1991-09-30 | 1995-02-14 | Merck Frosst Canada, Inc. | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5308850A (en) * | 1991-09-30 | 1994-05-03 | Merck Frosst Canada, Inc. | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5190968A (en) | 1991-09-30 | 1993-03-02 | Merck Frosst Canada, Inc. | (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
ZA928276B (en) | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
US5254567A (en) | 1991-11-15 | 1993-10-19 | Merck Frosst Canada, Inc. | Amorphous (quinolin-2-ylmethoxy)indole compounds which have useful pharmaceutical utility |
WO1993016069A1 (en) * | 1992-02-13 | 1993-08-19 | Merck Frosst Canada Inc. | (azaaromaticalkoxy)indoles as inhibitors of leukotriene biosynthesis |
CH683522A5 (de) | 1992-03-13 | 1994-03-31 | Hoffmann La Roche | Verfahren zur Herstellung von Diarylen. |
AU658729B2 (en) * | 1992-03-27 | 1995-04-27 | Kyoto Pharmaceutical Industries, Ltd. | 3-(1H-imidazol-1-ylmethyl)-1H-indole derivatives |
DE69314786T2 (de) | 1992-05-13 | 1998-02-19 | Syntex (U.S.A.) Inc., Palo Alto, Calif. | Substituierte indole als angiotensin ii antagonisten |
JPH0658881A (ja) | 1992-06-12 | 1994-03-04 | Mitsubishi Rayon Co Ltd | 光学活性化合物の絶対配置判定法、絶対配置判定用試薬及び絶対配置判定装置 |
US5334719A (en) | 1992-06-17 | 1994-08-02 | Merck Frosst Canada, Inc. | Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis |
AU4413893A (en) | 1992-06-22 | 1994-01-24 | Merck Frosst Canada Inc. | Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes |
US5314898A (en) | 1992-06-29 | 1994-05-24 | Merck & Co., Inc. | Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis |
US5314900A (en) | 1992-11-19 | 1994-05-24 | Merck Frosst Canada, Inc. | Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis |
US5288743A (en) | 1992-11-20 | 1994-02-22 | Abbott Laboratories | Indole carboxylate derivatives which inhibit leukotriene biosynthesis |
ZA939516B (en) | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
JP3457694B2 (ja) | 1993-02-04 | 2003-10-20 | 第一製薬株式会社 | インフルエンザ感染予防・治療薬 |
US5374635A (en) | 1993-03-29 | 1994-12-20 | Merck Frosst Canada, Inc. | Furo[3,2-b]pyridines and thieno[3,2-b]pyridines as inhibitors of leukotriene biosynthesis |
IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
JPH075651A (ja) | 1993-06-14 | 1995-01-10 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
KR960703120A (ko) | 1993-06-14 | 1996-06-19 | 알렌 제이. 스피겔 | 당뇨 및 비만 치료제로서의 2차아민(secondary amines as antidiabetic and antiobesity agents) |
EP0716650B1 (en) | 1993-09-03 | 1999-03-24 | Smithkline Beecham Plc | Indole and indoline derivatives as 5ht1d receptor antagonists |
DE4338770A1 (de) * | 1993-11-12 | 1995-05-18 | Matthias Dr Lehr | Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ |
US5399699A (en) | 1994-01-24 | 1995-03-21 | Abbott Laboratories | Indole iminooxy derivatives which inhibit leukotriene biosynthesis |
US5420282A (en) | 1994-02-15 | 1995-05-30 | Abbott Laboratories | Thiopyrano(2,3,4-c,d) indolyloxime ether alkylcarboxylates |
US5696076A (en) | 1994-06-22 | 1997-12-09 | Human Genome Sciences, Inc. | 5-lipoxygenase-activating protein II |
FR2721610B1 (fr) | 1994-06-28 | 1996-08-23 | Adir | Nouveaux dérivés (thia)cycloalkyl [b] indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
JPH0820532A (ja) | 1994-07-05 | 1996-01-23 | Dai Ichi Seiyaku Co Ltd | 抗膵炎剤 |
MX9700696A (es) | 1994-07-27 | 1997-04-30 | Sankyo Co | Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos. |
TW396200B (en) | 1994-10-19 | 2000-07-01 | Sumitomo Chemical Co | Liquid crystal composition and liquid crystal element containing such composition |
TW321649B (es) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
WO1996018393A1 (en) * | 1994-12-13 | 1996-06-20 | Smithkline Beecham Corporation | Novel compounds |
DE69622031T2 (de) * | 1995-04-10 | 2002-12-12 | Fujisawa Pharmaceutical Co., Ltd. | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN |
US5702637A (en) | 1995-04-19 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
EP0828712A1 (en) | 1995-05-10 | 1998-03-18 | Pfizer Inc. | Beta-adrenergic agonists |
JPH092977A (ja) | 1995-06-21 | 1997-01-07 | Dai Ichi Seiyaku Co Ltd | 経口投与用医薬組成物 |
EP1170009B1 (en) * | 1996-01-22 | 2004-04-07 | Fujisawa Pharmaceutical Co., Ltd. | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists |
EP0827943B1 (en) | 1996-01-29 | 2003-05-21 | Kaneka Corporation | Processes for the reduction of carbonyl compounds |
US5756531A (en) * | 1996-04-30 | 1998-05-26 | Abbott Laboratories | Iminoxy derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis |
US5750558A (en) * | 1996-06-06 | 1998-05-12 | Abbott Laboratories | Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis |
WO1997049703A2 (en) | 1996-06-25 | 1997-12-31 | Takeda Chemical Industries, Ltd. | Oxazolone derivatives and their use as anti-helicobacter pylori agents |
KR20000067946A (ko) | 1996-07-23 | 2000-11-25 | 스즈키 다다시 | 흡수 촉진제 |
US5877329A (en) | 1996-08-13 | 1999-03-02 | Merck & Co., Inc. | Palladium catalyzed indolization |
TR199901063T2 (xx) | 1996-11-14 | 1999-08-23 | Pfizer Inc. | �kame edilmi� piridinler i�in i�lem. |
GB9710523D0 (en) | 1997-05-23 | 1997-07-16 | Smithkline Beecham Plc | Novel compounds |
WO1998056757A1 (fr) | 1997-06-11 | 1998-12-17 | Sankyo Company, Limited | Derives de benzylamine |
GB9716657D0 (en) * | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
JPH1180032A (ja) | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 複合体 |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
ID27044A (id) * | 1997-12-24 | 2001-02-22 | Aventis Pharma Gmbh | Derivatif indole sebagai penghambat pada faktor xa |
WO1999033458A1 (fr) | 1997-12-25 | 1999-07-08 | Daiichi Pharmaceutical Co., Ltd. | Composition medicinale pour administration percutanee |
JPH11193265A (ja) | 1997-12-26 | 1999-07-21 | Dai Ichi Seiyaku Co Ltd | 3−(7−アミジノ−2−ナフチル)−2−フェニルプロピオン酸誘導体の塩 |
JPH11189531A (ja) | 1997-12-26 | 1999-07-13 | Dai Ichi Seiyaku Co Ltd | 経粘膜投与用医薬組成物 |
CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
BR9908280A (pt) | 1998-02-25 | 2000-10-31 | Genetics Inst | Inibidores de enzimas de fosfolipase |
EE200000522A (et) | 1998-02-25 | 2002-02-15 | Genetics Institute, Inc. | Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks |
US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
DE69933661T3 (de) | 1998-04-15 | 2012-01-26 | Merck Serono Biodevelopment | Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma |
US6867209B1 (en) | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
EP1080078B1 (en) * | 1998-05-22 | 2006-02-01 | Scios Inc. | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
JP2000007590A (ja) | 1998-06-23 | 2000-01-11 | Daicel Chem Ind Ltd | 置換芳香族化合物の製造方法 |
JP2002530077A (ja) | 1998-11-18 | 2002-09-17 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 炎症関連遺伝子 |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
JP2000302671A (ja) | 1999-04-27 | 2000-10-31 | Hitoshi Sezaki | 経口投与用医薬組成物 |
DE60036868D1 (de) * | 1999-05-21 | 2007-12-06 | Scios Inc | Derivate des indol-typs als p38 kinase inhibitoren |
EE200200149A (et) | 1999-09-21 | 2003-04-15 | Astrazeneca Ab | Kinasoliinühendid ja neid sisaldavad ravimkoostised |
DE19948417A1 (de) | 1999-10-07 | 2001-04-19 | Morphochem Ag | Imidazol-Derivate und ihre Verwendung als Arzneimittel |
AU7962200A (en) | 1999-10-29 | 2001-05-14 | Wakunaga Pharmaceutical Co., Ltd | Novel indole derivatives and drugs containing the same as the active ingredient |
JP2001139462A (ja) | 1999-11-10 | 2001-05-22 | Dai Ichi Seiyaku Co Ltd | 新規製剤 |
ATE375334T1 (de) | 1999-11-16 | 2007-10-15 | Boehringer Ingelheim Pharma | Harnstoff derivate als entzündungshemmende mittel |
AU2050001A (en) | 1999-12-16 | 2001-06-25 | Eli Lilly And Company | Synthesis of indole-containing spla2 inhibitors |
US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
GB0003079D0 (en) | 2000-02-10 | 2000-03-29 | Glaxo Group Ltd | Novel protein |
WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
NZ521192A (en) | 2000-03-09 | 2005-01-28 | Ono Pharmaceutical Co | Indole derivatives, process for preparation of the same and use thereof |
US6476037B1 (en) | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
US20010039037A1 (en) | 2000-04-05 | 2001-11-08 | Lee Harland | Novel polypeptide |
AU2001254790A1 (en) | 2000-04-07 | 2001-10-23 | Bayer Aktiengesellschaft | Regulation of human cyslt2-like gpcr protein |
AU2001259707A1 (en) | 2000-06-14 | 2001-12-24 | Warner Lambert Company | 6,5-fused bicyclic heterocycles |
WO2002000621A1 (fr) | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Composes inhibiteurs de la spla2 de type x |
DE10037310A1 (de) | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
IL155196A0 (en) | 2000-10-05 | 2003-11-23 | Fujisawa Pharmaceutical Co | Benzamide derivatives and pharmaceutical compositions containing the same |
JP2004529855A (ja) * | 2000-10-10 | 2004-09-30 | スミスクライン ビーチャム コーポレーション | 置換インドール類、そのような置換インドール類を含む医薬組成物及びPPAR−γ結合剤としてのそれらの使用 |
WO2002051397A1 (fr) | 2000-12-22 | 2002-07-04 | Ishihara Sangyo Kaisha, Ltd. | Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives |
MXPA03005432A (es) | 2000-12-22 | 2003-09-10 | Wyeth Corp | Compuestos de heterociclilindazol y -azaindazol como ligandos de 5-hidroxitriptamina-6. |
EP1425010B8 (en) | 2001-01-29 | 2012-03-28 | Janssen Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
JP2002226429A (ja) | 2001-02-06 | 2002-08-14 | Fuji Photo Film Co Ltd | アクリル酸エステル化合物の製造方法 |
EP1424335A4 (en) | 2001-09-07 | 2005-11-16 | Ono Pharmaceutical Co | INDOLE DERIVATIVES |
EP1424325A4 (en) | 2001-09-07 | 2005-12-21 | Ono Pharmaceutical Co | INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT |
US20030109550A1 (en) | 2001-09-19 | 2003-06-12 | Michael Clare | Substituted indazole compounds for the treatment of inflammation |
DE10147672A1 (de) | 2001-09-27 | 2003-04-10 | Bayer Ag | Substituierte 2,5-Diamidoindole und ihre Verwendung |
EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
AU2002226401A1 (en) | 2001-12-11 | 2003-06-23 | Rhodia Chimie | Catalytic pgm mixture for hydrosilylation |
USH2153H1 (en) | 2002-04-24 | 2006-04-04 | Smithkline Beecham Corp. | Association of asthma with polymorphisms in the cysteinyl leukotriene 2 receptor |
AU2003235236A1 (en) | 2002-05-13 | 2003-11-11 | Daiichi Pharmaceutical Co., Ltd. | Lyophilization product |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
WO2004000795A1 (ja) | 2002-06-20 | 2003-12-31 | Kyowa Hakko Kogyo Co., Ltd. | ビニルパーフルオロアルカンスルホン酸エステル誘導体の製造法 |
ES2271644T3 (es) * | 2002-06-24 | 2007-04-16 | Schering Corporation | Derivados de indol utiles como antagonistas de histamina h3. |
WO2004017920A2 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
WO2004017917A2 (en) * | 2002-08-26 | 2004-03-04 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
AU2003265681A1 (en) | 2002-08-29 | 2004-03-19 | Merck And Co., Inc. | Indoles having anti-diabetic activity |
WO2004048331A1 (en) | 2002-11-28 | 2004-06-10 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
US20040198800A1 (en) | 2002-12-19 | 2004-10-07 | Geoffrey Allan | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents |
GB0301350D0 (en) | 2003-01-21 | 2003-02-19 | Merck Sharp & Dohme | Therapeutic agents |
JP4513351B2 (ja) | 2003-02-12 | 2010-07-28 | チッソ株式会社 | 結合基にフッ素化されたアルキル基を有する液晶性化合物、液晶組成物および液晶表示素子 |
JPWO2004078719A1 (ja) | 2003-03-06 | 2006-06-08 | 小野薬品工業株式会社 | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
WO2004108671A1 (en) | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
EP1651231A4 (en) | 2003-07-24 | 2009-04-01 | Merck & Co Inc | CYCLOALKANES DIPHENYL-SUBSTITUTES, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND METHODS OF USE |
DE602004012873T2 (de) | 2003-08-25 | 2009-08-20 | Merck Patent Gmbh | Flüssigkristallines medium |
JP2007504238A (ja) | 2003-09-04 | 2007-03-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ポリ(adp−リボース)ポリメラーゼ(parp)の阻害剤としての置換インドール |
CN1878773A (zh) | 2003-09-05 | 2006-12-13 | 神经能质公司 | 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶 |
JP4363133B2 (ja) | 2003-09-09 | 2009-11-11 | 東洋インキ製造株式会社 | 有機エレクトロルミネッセンス用素子材料およびそれを用いた有機エレクトロルミネッセンス素子 |
US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
PT1678185E (pt) * | 2003-10-31 | 2009-01-13 | Otsuka Pharma Co Ltd | Compostos 2,3-di-hidro-6-nitroimidazo[2,1-b]oxazole para o tratamento da tuberculose |
JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
CA2547212A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
EP1690538A4 (en) | 2003-12-02 | 2009-02-25 | Shionogi & Co | ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR |
CN1886372A (zh) | 2003-12-03 | 2006-12-27 | 默克公司 | 用于治疗阿尔茨海默病及相关病症的1-烷基-3-硫-取代的吲哚-2-链烷酸 |
WO2005066151A2 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
JP5142450B2 (ja) | 2003-12-25 | 2013-02-13 | 徹也 西尾 | ジアミノ化合物、ビニル化合物、高分子化合物、配向膜、該配向膜を用いた有機半導体装置、導電性高分子、該導電性高分子を使用したエレクトロルミネッセンス素子、液晶配向膜、及び該液晶配向膜を用いた光学素子 |
US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
WO2005066157A1 (en) | 2004-01-02 | 2005-07-21 | Suven Life Sciences | 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators |
JP2005194250A (ja) | 2004-01-09 | 2005-07-21 | Sumitomo Chemical Takeda Agro Co Ltd | トリアゾール化合物、その製造法および用途 |
US8158362B2 (en) | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
US20070197585A1 (en) | 2004-02-26 | 2007-08-23 | Jilly Evans | Use of cysteinyl leukotriene 2 receptor antagonists |
WO2005097203A2 (en) | 2004-04-01 | 2005-10-20 | Cardiome Pharma Corp. | Serum protein conjugates of ion channel modulating compounds and uses thereof |
JP2007534702A (ja) | 2004-04-26 | 2007-11-29 | バンダービルト・ユニバーシティ | 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体 |
MXPA06012683A (es) * | 2004-05-03 | 2007-01-16 | Hoffmann La Roche | Derivados de indolilo como moduladores de receptor x del higado. |
ATE416161T1 (de) | 2004-06-18 | 2008-12-15 | Biolipox Ab | Zur behandlung von entzündungen geeignete indole |
CA2571789A1 (en) * | 2004-07-02 | 2006-02-09 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
US8207172B2 (en) | 2004-08-20 | 2012-06-26 | Bayer Intellectual Property Gmbh | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006041961A1 (en) | 2004-10-05 | 2006-04-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES | Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
EP1814877B1 (en) | 2004-10-18 | 2009-03-11 | Merck & Co., Inc. | Diphenyl substituted alkanes as flap inhibitors |
CA2594422A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as cell cycle kinase inhibitors |
EP1844013A1 (en) | 2005-01-19 | 2007-10-17 | Biolipox AB | Indoles useful in the treatment of inflammation |
EP1841736A1 (en) | 2005-01-19 | 2007-10-10 | Biolipox AB | Indoles useful in the treatment of inflammation |
CA2594773A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
ATE501119T1 (de) | 2005-01-19 | 2011-03-15 | Biolipox Ab | Entzündungshemmende indol-derivate |
CA2600860A1 (en) | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use |
JP5677719B2 (ja) * | 2005-04-21 | 2015-02-25 | メルク セローノ ソシエテ アノニム | 2,3置換ピラジンスルホンアミド |
JP5846711B2 (ja) | 2005-06-09 | 2016-01-20 | メダ アーベー | 炎症性疾患の治療のための方法及び組成物 |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
EP1947942B1 (en) | 2005-08-18 | 2015-07-29 | Accelalox, Inc. | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
ATE539069T1 (de) | 2005-10-11 | 2012-01-15 | Univ Pittsburgh | Isotopenmarkierte benzofuranverbindungen als bilddarstellende mittel für amyloidogene proteine |
JP2009512716A (ja) | 2005-10-21 | 2009-03-26 | ユニバーシティ・オブ・アラバマ・アット・バーミンガム | Hiv−1キャプシド構築の低分子阻害剤 |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
UY29896A1 (es) | 2005-11-04 | 2007-06-29 | Astrazeneca Ab | Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US20070244128A1 (en) | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
UY29892A1 (es) | 2005-11-04 | 2007-06-29 | Astrazeneca Ab | Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
AR059901A1 (es) | 2006-03-20 | 2008-05-07 | Bayer Pharmaceuticals Corp | Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares. |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
JP5564251B2 (ja) | 2006-06-29 | 2014-07-30 | キネックス ファーマシューティカルズ, エルエルシー | キナーゼカスケードを調節するためのビアリール組成物および方法 |
JP2009023986A (ja) | 2006-11-08 | 2009-02-05 | Pharma Ip | 抗癌剤としてのビアリール誘導体 |
EP3048099A3 (en) | 2006-11-15 | 2016-09-21 | YM BioSciences Australia Pty Ltd | Inhibitors of kinase activity |
EP2086531A4 (en) | 2006-11-30 | 2009-09-30 | Amira Pharmaceuticals Inc | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS |
EP2114876A4 (en) | 2007-02-05 | 2010-12-22 | Amira Pharmaceuticals Inc | INVERSE INDOLES AS INHIBITORS OF THE 5-LIPOXYGENASE ACTIVATION PROTEIN (FLAP) |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
WO2009002746A1 (en) | 2007-06-22 | 2008-12-31 | Decode Genetics Ehf. | Dosing schedules of leukotriene synthesis inhibitors for human therapy |
US8124605B2 (en) | 2007-07-06 | 2012-02-28 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
US20100298343A1 (en) | 2007-10-05 | 2010-11-25 | John Howard Hutchinson | 5-lipoxygenase-activating protein (flap) inhibitors |
TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
WO2009114865A2 (en) | 2008-03-14 | 2009-09-17 | National Jewish Health | Methods to determine susceptibility to treatment with leukotriene modifiers |
BRPI0912267A2 (pt) | 2008-05-23 | 2015-10-13 | Amira Pharmaceuticals Inc | sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável. |
US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US20120027842A1 (en) | 2008-12-23 | 2012-02-02 | Amira Pharmaceuticals, Inc. | Topical formulations of flap inhibitors for administration to an eye |
-
2006
- 2006-10-31 GB GB0621651A patent/GB2431927B/en not_active Expired - Fee Related
- 2006-11-03 EP EP06836946A patent/EP1943266A4/en not_active Withdrawn
- 2006-11-03 BR BRPI0618047-7A patent/BRPI0618047A2/pt not_active IP Right Cessation
- 2006-11-03 JP JP2008540097A patent/JP2009514959A/ja active Pending
- 2006-11-03 TW TW102131359A patent/TW201402562A/zh unknown
- 2006-11-03 JP JP2008539090A patent/JP5320590B2/ja not_active Expired - Fee Related
- 2006-11-03 CA CA002628233A patent/CA2628233A1/en not_active Abandoned
- 2006-11-03 CA CA002628467A patent/CA2628467A1/en not_active Abandoned
- 2006-11-03 AR ARP060104837A patent/AR057872A1/es not_active Application Discontinuation
- 2006-11-03 SG SG201006712-2A patent/SG165387A1/en unknown
- 2006-11-03 AR ARP060104838A patent/AR056214A1/es not_active Application Discontinuation
- 2006-11-03 WO PCT/US2006/043095 patent/WO2007056220A2/en active Application Filing
- 2006-11-03 AU AU2006311796A patent/AU2006311796A1/en not_active Abandoned
- 2006-11-03 EP EP06827508A patent/EP1942896A4/en not_active Withdrawn
- 2006-11-03 TW TW095140880A patent/TW200804276A/zh unknown
- 2006-11-03 AU AU2006311804A patent/AU2006311804A1/en not_active Abandoned
- 2006-11-03 WO PCT/US2006/043108 patent/WO2007056228A2/en active Application Filing
- 2006-11-03 KR KR1020087013546A patent/KR20080066989A/ko not_active Application Discontinuation
- 2006-11-03 EA EA200801164A patent/EA200801164A3/ru unknown
- 2006-11-03 US US12/089,706 patent/US8841295B2/en not_active Expired - Fee Related
- 2006-11-03 TW TW095140834A patent/TW200804334A/zh unknown
- 2006-11-06 AR ARP060104861A patent/AR056215A1/es not_active Application Discontinuation
- 2006-11-06 TW TW095141065A patent/TW200804277A/zh unknown
-
2007
- 2007-10-27 US US11/925,841 patent/US7834037B2/en not_active Expired - Fee Related
-
2008
- 2008-04-15 IL IL190872A patent/IL190872A0/en unknown
- 2008-04-16 NO NO20081839A patent/NO20081839L/no not_active Application Discontinuation
- 2008-04-30 CR CR9949A patent/CR9949A/es not_active Application Discontinuation
- 2008-05-05 MA MA30901A patent/MA29932B1/fr unknown
-
2010
- 2010-10-18 US US12/906,325 patent/US20110034514A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057872A1 (es) | Inhibidores de la proteina activadora de 5-lipoxigenasa (flap) | |
AR066424A1 (es) | Inhibidores de proteina activada de la 5- lipoxigenasa ( flap) | |
AR066445A1 (es) | Inhibidores de la proteina activadora de la 5- lipoxigenasa (flap) | |
EA200800476A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
AR062510A1 (es) | Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos | |
AR077505A1 (es) | Compuestos de piridina y sus usos | |
AR051469A1 (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
RU2008142834A (ru) | Модуляция церамидкиназы | |
PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
AR065280A1 (es) | Agentes antiparasitarios | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
BRPI0606524A2 (pt) | derivados de indol para o tratamento de infecções virais | |
AR075731A1 (es) | Derivados heterociclicos de bencimidazoles, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento del virus sincicial respiratorio(vsr). | |
CL2011002016A1 (es) | Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc). | |
AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
NO20084742L (no) | Aziridinyl-epotilonforbindelser | |
AR054231A1 (es) | Composiciones farmaceuticas | |
AR048808A1 (es) | Pirrolocarbazoles fusionados | |
AR059018A1 (es) | Derivados de 6- fenil -1h- imidazo (4,5-c) piridina -4- carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina s y/o catepsina k | |
AR101566A2 (es) | Composición farmacéutica de compuestos heterobicíclicos que contienen nitrógeno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |